Mallinckrodt announced that the Irish High Court has given the necessary ruling to enable its combination with Endo, advancing the companies' plan to merge in a stock and cash transaction that will create a global, scaled, diversified therapeutics leader.
The Court's ruling is the final substantive legal step required for the transaction and follows a vote by each company's shareholders last month to approve the merger. With these approvals in hand, Mallinckrodt and Endo expect to complete their combination in early August, pending the satisfaction of the remaining closing steps. Mallinckrodt's headquarters in Dublin, Ireland, will serve as the combined company's global headquarters.
"The ruling from the Irish High Court brings us one step closer to creating a new future for our companies," said Siggi Olafsson, President and Chief Executive Officer of Mallinckrodt, who will also serve as the President and CEO of the combined company. "We have an extraordinary opportunity to combine two essential pharmaceutical organizations to accelerate value creation for our shareholders, customers, and employees, for the ultimate benefit of the patients we serve. Our excitement for the future continues to grow."
As initially announced on March 13, 2025, Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after the close of the transaction and to separate that business from the combined company at a later date. The separation would be subject to approval by the combined company's Board of Directors and other conditions.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!